US Edition$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Vigil Neuroscience, Inc. (NASDAQ: VIGL)
- On May 21, 2025, Sanofi revealed it has entered into a deal to purchase Vigil Neuroscience, a biotech company focused on neurodegenerative disease therapies, with the transaction anticipated to finalize in the third quarter of 2025.
- Sanofi’s purchase of Vigil builds on its earlier $40 million investment in June 2024 and underscores its commitment to neurology and addressing significant unmet medical challenges.
- Vigil develops VG-3927, a compound preparing for a Phase II Alzheimer’s trial, which Sanofi aims to accelerate by leveraging its resources and network.
- The transaction values Vigil around $600 million, with an upfront cash payment of $8.00 per share plus a contingent $2.00 per share linked to VG-3927’s sales.
- Class action attorney Juan Monteverde is investigating the merger, while Sanofi asserts the deal supports its strategic goals and does not affect 2025 financial guidance.
13 Articles
13 Articles
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Vigil Neuroscience, Inc. (NASDAQ: VIGL)
NYC, May 24, 2025 (GLOBE NEWSWIRE) -- NEW YORK, May 24, 2025 / GlobeNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Vigil Neuroscience, Inc. (NASDA…
Sanofi to acquire Vigil Neuroscience, adding Alzheimer’s disease candidate to early-stage pipeline - Pharmafile
Sanofi has announced an agreement to acquire Vigil Neuroscience, a biotech company focused on therapies for neurodegenerative diseases. The deal will add VG-3927, a candidate for Alzheimer’s disease (AD) that is ready for a phase 2 trial, to Sanofi’s early-stage neurology portfolio. VG-3927 is an oral small molecule agonist of TREM2, a receptor involved in […] The post Sanofi to acquire Vigil Neuroscience, adding Alzheimer’s disease candidate to…
Coverage Details
Bias Distribution
- 75% of the sources lean Left
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
